Nervous system disorders caused by human immunodeficiency virus (HIV) infection involve the central or peripheral nervous systems in over 50% of infected individuals at some point during the course of infection. Most disorders of the nervous system become clinically evident with advancing immunosuppression during the acquired immunodeficiency syndrome (AIDS) phase of disease (Table 1). Almost 65 million people globally have been infected with the HIV since it was first identified in the early 1980’s. In Canada over 60,000 persons are estimated to be infected with HIV, principally HIV-1. The HIV-1 B clade is the predominant HIV-1 subtype causing infection in the industrialized world and hence, the disorders discussed herein are those most thoroughly described for HIV-1 B infections. Within Canada, groups at high or increasing risk for HIV infection include men having sex with men, injection drug users, Aboriginal peoples, women, youth, inmates and peoples from endemic regions such as sub-Saharan Africa. With the
advent of highly active antiretroviral therapy in the mid-1990’s, many HIV-1 seropositive individuals in industrialized countries now live upwards of 20 years after initial infection, long after they have developed AIDS. Given the rising prevalence of HIV infection globally including Canada, there is a high likelihood of practicing physicians encountering patients with HIV infection and often with a neuropsychiatric disorder.

There are two major groups of nervous system disorders frequently encountered during HIV-1 infection including opportunistic infections and primary neurological disorders. Opportunistic infections of the central and peripheral nervous systems arise as consequences of HIV-induced immunosuppression and consist of Toxoplasma encephalitis, Cryptococcal meningitis, Progressive Multifocal Leukoencephalopathy, primary central nervous system lymphoma, central nervous system tuberculosis, cytomegalovirus encephalitis and radiculitis, or multidermal herpes zoster (Table 1) (reviewed in 4,5). These conditions are rarely seen in encephalitis and radiculitis, or multidermatomal herpes zoster (Table 1) (reviewed in 4,5). These conditions are rarely seen in patients in ongoing care and receiving highly active antiretroviral therapy. The neurological syndromes, assumed to be caused directly by HIV-1 infection, have emerged as the more common nervous system disorders in industrialized countries’ clinics. These latter disorders are often subtle and are frequently under-recognized because concurrent illnesses or drug-related effects. Despite the availability of highly active antiretroviral therapy, HIV-related neurological disorders continue to represent substantial personal, economic and societal burdens with worsened quality of life, employability, survival and are often complicated by mental health issues. This review examines the principal neurological disorders associated with HIV infection including their diagnosis and treatment based on review of the literature using key words (HIV, dementia, neuropathy, seizure, antiretroviral therapy) for searching electronic and print databases, together with our collective clinical experience. Like many areas in medicine, particularly neurology and psychiatry, the diagnosis of the disorders reviewed in this manuscript is largely predicated on syndromic recognition and not definitive or quantitative diagnostic tests although the long term goal is to establish evidence-based and widely applicable tools for diagnosis. We also use the descriptor, neuropsychiatric, because there is often overlap of all of the disorders discussed herein with mental health issues including affective disorders or addiction, which shape the disease phenotype in terms of presentation and response to treatment(s).

### HIV neurological disorders

This group of syndromes reflects HIV-1’s immediate and deleterious effects on neural cells, causing damage to the brain, spinal cord, and peripheral nerves in adults and adolescents. The most common of these primary HIV-associated neuropsychiatric illnesses include HIV-associated dementia (also termed AIDS Dementia Complex or HIV encephalopathy) and distal sensory polyneuropathy, which is frequently exacerbated by antiretroviral drug toxicity. Other central and peripheral nervous system disorders complicate the course of HIV-1 infection including seizures, myelopathy, aseptic meningitis, multiple neuropathies and myopathies (Table 2). The estimated overall prevalence of nervous system disorders among patients receiving highly active antiretroviral therapy but also requiring neurological care is over 25% (Power and Gill, unpublished) although autopsy studies suggest upwards of 90% of HIV/AIDS patients exhibit neuropathological changes. Unfortunately, the incidence and prevalence of HIV-related nervous system disorders is not established in Canada, although data from our clinics indicate that the prevalence of neurological disease is high (peripheral neuropathy, 41%; neurocognitive impairment, 25% seizure/epilepsy, 20.7%; CNS opportunistic infections, 14.7%) (Power and Gill, unpublished). The individual neurological syndrome can often be predicted in the context of the CD4+ T lymphocyte level in blood (Figure 1) or by estimating the time from original infection (Figure 2). For example, HIV-associated dementia and distal sensory polyneuropathy are typically features of AIDS, while antiretroviral toxic neuropathy and a less severe neurocognitive disorder termed Minor Neurocognitive Disorder, frequently antecedent to HIV-associated dementia, may present earlier in the disease course at higher CD4+ T cell levels in blood. Human immunodeficiency virus-associated dementia and Minor Neurocognitive Disorder have been termed collectively as HIV-associated Neurocognitive Disorder.

### Clinical Case

A 38-year-old homosexual Caucasian male accountant was referred to an HIV care clinic with a recent diagnosis of HIV/AIDS based on HIV-1 positive serology, reduced CD4+ T cell count (150 cells/µL) and a concurrent diagnosis of *Pneumocystis jiroveci* pneumonia. In the course of evaluation for potential highly active antiretroviral therapy, it became evident from the patient and his family that he was progressively more forgetful, confused intermittently, agitated but also displayed psychomotor slowing. His work performance had substantially deteriorated over the preceding three months. There was no history of drug abuse or familial cognitive impairment. Physical exam disclosed a masked face, interrupted saccadic eye movements, plastic rigidity in all limbs, a stooped shuffling gait, hyperreflexia, including a brisk jaw jerk. The HIV Dementia Scale score was 8/16 while the Folstein Mini-Mental State Examination score was 27/30. Neuropsychological testing revealed impaired performance on Symbol-Digit, Trail Making A and B and Grooved Pegboard testing (greater than two standard deviations below the age-adjusted mean for all tests). A brain magnetic resonance image revealed cerebral cortical atrophy on T1-weighted image (Figure 3A) with increased diffuse white matter signal in periventricular regions, on T2-weighted (Figure 3B) and FLAIR (Figure 3C) images. Cerebrospinal fluid analysis disclosed increased protein (0.8 g/L), normal glucose (4.0 mmol/L) with a pleocytosis (14×10^6/L cells; 90% lymphocytes) and no other pathogens (tuberculosis, cryptococcus, varicella zoster virus, herpes simplex-1, entovirosc, JC virus) were detected by PCR or on microscopy. Other investigations of blood (thyroid stimulating hormone, vitamin B12, VDRL test, renal and hepatic parameters) were unremarkable. The plasma viral load was 10^5 copies/ml while the cerebrospinal fluid viral load was 10^4 copies/ml. The patient was diagnosed with HIV-associated dementia based on clinical presentation, physical examination, neuroimaging, cerebrospinal fluid and blood tests, and neuropsychological assessment. Highly active antiretroviral therapy was started including zidovudine, lamivudine and...
ritonavir-lopinavir. In addition, the patient and his family were provided with in-home assistance as he was unable to care for himself and his personal matters through social work and occupational therapy. Three months later, the patient was reassessed in the clinic and found to be living semi-independently requiring only limited support from family and the community. However, he had developed painful feet at night with allodynia, reduced vibratory and temperature sensation in the feet and absent deep tendon reflexes in the ankles. He had no systemic risk factors (diabetes, hepatitis B and C virus infections, hypothyroidism, syphilis) for peripheral neuropathy except for HIV infection. He was diagnosed with distal sensory polyneuropathy based on clinical findings and nerve conduction studies showing an axonal neuropathy. The patient was treated with gabapentin 300 mg three times per day and his pain subsided. Within six months the patient was living independently and was considering a return to work on a part-time basis (See Question and Answer Section).

HIV neuropathogenesis

The pathobiology of primary HIV-related neurological disorders is defined by both neuroinflammation and neuronal injury (Figure 4) (reviewed in10). Human immunodeficiency virus invades the central and peripheral nervous systems soon after initial infection through HIV-infected mononuclear cells (macrophages and CD4+ T cells) traversing the blood-brain or –nerve barriers (neuroinvasion) with ensuing tissue infiltration. Within the nervous system, HIV subsequently infects resident microglia, perivascular macrophages and astrocytes but not neurons or oligodendrocytes (neurotropism). Infection of cells in the nervous system is largely mediated by CD4 and the chemokine receptor, CCR5, serving as viral receptors. The development of nervous system disease (neurovirulence) occurs through two non-cell autonomous mechanisms including cytotoxic effects of (a) HIV-encoded proteins (gp120, Vpr and Tat) or (b) host molecules (cytokines, chemokines, eicosanoids, free radicals, proteases). These viral and host molecules are secreted by activated or infected microglia/macrophages. Chronic exposure of neurons, astrocytes or Schwann cells to these secreted molecules culminates in neuronal process retraction (synaptic injury or peripheral nerve) and eventual cell death (Figure 4). While neuronal apoptosis has garnered substantial attention in the literature, it is becoming apparent that other types of programmed cell death (autophagy) and necrosis likely contribute to reduced neural cell viability and survival10.

The neuropathological hallmarks of advanced HIV infection of the central nervous system include HIV encephalitis defined by multinucleated giant cells, perivascular cuffs, comprised of macrophages and lymphocytes, diffuse white matter pallor, viral antigen detection with ensuing neuronal or synapto-dendritic loss, which are often present and are correlated with magnetic resonance imaging and spectroscopy findings11-13. In the peripheral nervous system, damage to neuronal soma in the
dorsal root ganglion and a dying back pattern of axonal injury is apparent, particularly in small diameter myelinated and unmyelinated sensory axons, together with infiltrating leukocytes (macrophages and lymphocytes). While HIV-1 genome and protein can be detected in both the central and peripheral nervous systems, viral abundance in nervous system tissue in terms of viral RNA, DNA or protein does not seem to be predictive of the diagnoses of HIV-associated dementia or distal sensory neuropathy. There is compelling evidence from models of HIV infection including simian and feline immunodeficiency virus infections that individual viral strains and the sequences of specific viral genes contribute to neuropathogenesis (reviewed in16). While HIV-1 neuroinvasion and neurotropism occurs in all HIV-infected persons, clinically evident disease or neurovirulence affects only a subset of HIV-infected patients, likely due to specific susceptibility variables (neurosusceptibility), outlined for each disorder in the following sections.

Central nervous system disorders of HIV-1 infection

HIV-associated dementia

The development of HIV-associated dementia is among the most devastating consequences of HIV-1 infection because of its unique and progressive clinical manifestations. Human immunodeficiency virus-associated dementia is an AIDS-defining illness (Table 1) and approximately 15-30% of untreated AIDS patients acquire the diagnosis. Conversely, in populations receiving highly active antiretroviral therapy, the current estimated prevalence of HIV-associated dementia is 10% with an incidence of 1%/17.

Figure 3: Cranial magnetic resonance imaging of a 38-year-old HIV-1 seropositive male with HIV-associated dementia. (A) T1-weighted image shows hydrocephalus due to central atrophy accompanied by cortical atrophy. (B) T2-weighted image shows enlarged ventricles with increased diffuse white matter signal. (C) FLAIR image exhibits extensive white matter changes with cortical atrophy.

Clinical features

This syndrome is characterized by a clinical triad including neurocognitive impairments (forgetfulness, poor concentration and comprehension, slowed mental processing), emotional disturbances (agitation, apathy), and motor dysfunctions (tremor, bradykinesia, ataxia and spasticity) (Table 3). These signs and symptoms become manifest over weeks to months. Both patients and caregivers are aware of the deterioration in neurological performance and their concerns should be heeded closely (See clinical case). However, HIV-associated dementia displays diversity in its clinical phenotype, including movement disorders18-20 and occasionally mania or psychosis21,22. Symptoms typically begin once an individual’s CD4+ T cell counts drop below 200 cells/μl of blood although with the advent of highly active antiretroviral therapy, HIV-associated dementia is now presenting at higher CD4+ T cell levels. In a large part, the earlier onset of HIV-associated dementia is likely due to limited CNS penetrance by antiretroviral drugs, allowing the virus to replicate in a protected reservoir. The course of HIV-associated dementia is highly variable from patient to patient, and can present as an abrupt decline over a few weeks or a protracted course over several months23. Clinical risk factors for HIV-associated dementia include low CD4+ T cell levels, high viral set point early in the infection course, increased viral load in cerebrospinal fluid (CSF), anemia, extremes of age, low body-mass index, injection drug use, both host and viral genetic polymorphisms and possibly female gender and concurrent hepatitis C virus infection1,24.

The estimated prevalence of Minor Neurocognitive Disorder, which may precede HIV-associated dementia, is 20-30% of all HIV-infected patients and may be complicated by co-morbidities including chronic substance abuse, affective disorders previous
injury or prior opportunistic infection of the central nervous system. Minor Neurocognitive Disorder presents with the clinical hallmarks of HIV-associated dementia, albeit with less severe signs and symptoms and at higher CD4+ T cell levels. Indeed, many patients display features of Minor Neurocognitive Disorder that are unrecognized, especially among patients receiving highly active antiretroviral therapy and are apparently virologically ‘suppressed’ based on undetectable virus in plasma. Again, these less intrusive neuropsychiatric signs and symptoms require attention as they can contribute to an individual’s inability to function effectively in the workplace and at home. The diagnoses of HIV-associated dementia or Minor Neurocognitive Disorder herald a worsened survival prognosis, even in the era of highly active antiretroviral therapy. The presence of neurocognitive impairment also adversely affects adherence to medications, which may underlie the worsened survival among these patients.

**Diagnosis**

Radiological features accompanying HIV-associated dementia include cerebral and basal ganglia atrophy and diffuse periventricular white matter hyperintensities on magnetic resonance imaging T2 weighted images (Figure 4), although non-demented HIV/AIDS patients may display less severe but similar radiological changes. Magnetic resonance spectroscopy shows diminished N-acetyl-aspartate levels, a neuronal metabolite together with increased choline levels indicative of inflammation. Positron emission tomography reveals variable findings in HIV-associated dementia although basal ganglia hypometabolism is a late-stage common feature. Other valuable investigations include cerebrospinal fluid analyses to exclude opportunistic infections; high protein and IgG levels with an accompanying pleocytosis are found in cerebrospinal fluid of 66% of HIV-associated dementia patients. Cerebrospinal fluid HIV-1 copy number together with markers of immune dysregulation (neopterin, β-2-microglobulin, chemokines) are associated with the presence of HIV-associated dementia but remain uncertain diagnostic markers.

Neuropsychological assessment is a valuable tool in confirming the diagnosis of HIV-associated dementia and also evaluating the response to therapy. Given that HIV preferentially infects and affects the basal ganglia and deep white matter, HIV-associated dementia predictably displays the cardinal features of a “sub-cortical dementia”. Hence, HIV-associated dementia is not readily detected by the Folstein Mini-Mental Status Exam unless the patient is severely demented. More useful screening tools for HIV-associated dementia include the HIV Dementia Scale with a sensitivity and specificity exceeding 80% and derivatives thereof, the Mental Alteration Test, the Executive Interview, and the HIV Dementia Assessment. The Memorial Sloan-Kettering Scale is a widely accepted tool for monitoring the progression and disability of dementia over time. A more detailed neuropsychological evaluation is often imperative (Symbol-Digit, Grooved Pegboard, Trail Making A and B) in circumstances of co-morbidities (prior head injury, drug abuse) but requires experienced interpretation. It is important to consider that the presence of marked immunosuppression, high viral loads in the CSF, prototypic changes on cranial magnetic resonance imaging are associated with HIV-associated dementia and Minor Neurocognitive Disorders but the diagnosis rests on the overall presentation of clinical features together with supporting laboratory evidence.

**Differential diagnosis**

The differential diagnoses for HIV-associated Dementia/ Minor Neurocognitive Disorder are broad with an immediate need to exclude other treatable infections that are common in HIV/AIDS patients, including Cryptococcal meningitis, Toxoplasmic encephalitis, Progressive Multifocal Leukoencephalopathy and Cytomegalovirus encephalitis. The combination of neuroimaging and cerebrospinal fluid analyses is usually sufficient to exclude these infections. A history of past or current substance abuse is essential to ascertain, permitting exclusion of delirium or residual neuropsychiatric deficits, especially evident with long-standing crack/cocaine use. A paradoxical deterioration in neurological status following initiation of highly active antiretroviral therapy is termed Neurological Immune Reconstitution Inflammatory Syndrome (NeuroIRIS) and requires exclusion based on history and neuroimaging. Other neurodegenerative disorders including Alzheimer’s disease and vascular dementia are becoming more prevalent as the HIV/AIDS population ages. Again, neuropsychological profile coupled with neuroimaging and cerebrospinal fluid analysis will permit detection of these disorders. Finally, given the evolving demographics of HIV infection, especially in North America and Europe, it is essential to evaluate other causes of neurocognitive impairment such as head injury, hepatitis C virus infection and pre-existing or concurrent neuropsychiatric disorders (schizophrenia, depression, anxiety disorders, sleep disorders).

**Treatment**

The most effective therapy for HIV-associated dementia is treatment of the underlying HIV infection with highly active antiretroviral therapy. Highly active antiretroviral therapy usually consists of two nucleoside analogue reverse transcriptase inhibitors and either a ritonavir-boosted protease inhibitor or a non-nucleoside analogue reverse transcriptase inhibitor. Neuropsychological performance shows improvement in HIV/AIDS patients treated with either two nucleoside analogue reverse transcriptase inhibitors and the non-nucleoside analogue reverse transcriptase inhibitor, nevirapine, or with two nucleoside analogue reverse transcriptase inhibitors and a protease inhibitor. Specific antiretroviral drugs have higher central nervous system penetration than others, including zidovudine (nucleoside analogue reverse transcriptase inhibitor), stavudine (d4T) (nucleoside analogue reverse transcriptase inhibitor), abacavir (nucleoside analogue reverse transcriptase inhibitor), efavirenz (non-nucleoside analogue reverse transcriptase inhibitor), and indinavir (protease inhibitor). Highly active antiretroviral therapy shows some benefit in reversing progressive HIV-associated dementia although poor drug penetration into the central nervous system still limits highly active antiretroviral therapy’s efficacy, and thus, other agents have been investigated for their potential neuroprotective properties. It is clear that highly active antiretroviral therapy will contribute to some improvement of signs and symptoms in HIV-
associated dementia/Minor neurocognitive disorder patients who are highly active antiretroviral therapy-naïve but in patients who have been exposed previously to highly active antiretroviral therapy, the benefits of a new antiretroviral drug regimen are less evident\textsuperscript{53}. This lack of highly active antiretroviral therapy-associated benefit is most evident for patients who exhibit a plateau or “burned out” phase of HIV-associated dementia\textsuperscript{54}. Indeed, some patients receiving highly active antiretroviral therapy show continued neuropsychiatric disease progression despite systemic viral suppression, presumably due to persistent viral replication, neuroimmune activation and ensuing neurodegeneration.

Other neuroprotective strategies for HIV-associated dementia have been investigated\textsuperscript{1}. While selegiline was thought initially to exert some neuroprotective effects, a recent randomized controlled trial failed to show any benefit\textsuperscript{55}. Although memantine is beneficial in the treatment of Alzheimer’s disease and in experimental models of HIV-associated dementia, a recent clinical trial did not show benefits in the primary endpoint, neuropsychological performance, after four months of treatment\textsuperscript{56}, which was likely due to the trial being underpowered. Our clinical experience suggests that the closely related drug, amantidine, is also beneficial in HIV-associated dementia patients, especially with marked motor features. The matrix metalloproteinase (MMP) inhibitor, prinomastat\textsuperscript{57} as well as other MMP inhibitors have been shown to block HIV-induced neurotoxicity experimentally and may thus be useful for patients with HIV-associated dementia. Human growth hormone has been shown to be neuroprotective, and may be a component of HIV-associated dementia treatment in the future\textsuperscript{58}. Other neurotrophic and neuroprotective factors are currently being developed for the treatment of HIV-associated dementia including minocycline, which suppresses microglia/macrophage activation\textsuperscript{59}, as well as valproic acid\textsuperscript{60} with some conflicting data\textsuperscript{61} and newer antiretroviral drugs including viral receptor antagonists and integrase inhibitors.

**Neurological Immune Reconstitution Inflammatory Syndrome (NeuroIRIS)**

A subset of highly active antiretroviral therapy-treated patients experience a paradoxical deterioration in their neurological status, usually at the initiation of highly active antiretroviral therapy\textsuperscript{62}. This onset of neurological signs and symptoms or worsening of prior neurological disabilities is often apparent in patients with very low CD4\(^+\) T cell counts and a concurrent central nervous system opportunistic infection; the clinical worsening occurs as plasma viral suppression begins and has been termed the Neurological Immune Reconstitution Inflammatory Syndrome. NeuroIRIS presents as focal central nervous system deficits including ataxia, hemiparesis and confusion, cerebrospinal fluid pleocytosis and both white matter and cortical abnormalities in neuroimaging (magnetic resonance imaging) and is frequently observed in the context of pre-existing Progressive Multifocal Leuko-encephalopathy, Cryptococcal meningitis and occasionally HIV-associated dementia\textsuperscript{63}. Neuropathological studies of Neurological Immune Reconstitution Inflammatory Syndrome disclose widespread leukocyte infiltrates in the brain, frequently proximal to the pre-existing infection\textsuperscript{64}. The extent of neuropsychiatric disability varies widely but may respond to treatment with glucocorticoids but the full impact of Neurological Immune Reconstitution Inflammatory Syndrome in terms of both epidemiology and underlying pathogenesis warrants greater study.
Other HIV-related CNS disorders (Table 2)

Other neurological disorders arising due to the direct effects of HIV infection of the CNS include vacuolar myelopathy and seizures. Vacuolar myelopathy is a progressive inflammatory degenerative disorder of the cervical and thoracic spinal cord, resulting in leg weakness and spasticity, increasing sensory loss, bladder dysfunction and occasionally neuropathic pain\(^65\). Vacuolar myelopathy is clinically evident in approximately 5-10% of untreated HIV/AIDS patients and usually occurs in very immunosuppressed individuals but has become less prevalent with the advent of highly active antiretroviral therapy; among treated patients, the only signs may be brisk deep tendon reflexes in the legs and mild gait ataxia. Neuropathological studies show intense macrophage activation and infiltration affecting over 50% of untreated HIV/AIDS patients at autopsy\(^66\). Vacuolar myelopathy needs to be distinguished from other myelopathies including vitamin B12 deficiency, HTLV-1 myelopathy and varicella zoster virus, syphilitic, tuberculous, or acute transverse myelitis. Neuroimaging (magnetic resonance imaging) and cerebrospinal fluid analysis are often normal in vacuolar myelopathy except for spinal cord atrophy but are essential for excluding other myelopathic conditions. Limited improvement in signs and symptoms associated with vacuolar myelopathy is usually observed with the introduction of highly active antiretroviral therapy, often leaving patients dependent on walking aids, together with medical treatment for a neurogenic bladder and lower limb spasticity.

Seizures are common (5-10% prevalence) among HIV-infected persons due to opportunistic infections, pre-morbid conditions (head injury) or direct consequences of HIV-infection\(^67\). Both complex partial and generalized seizures are frequently encountered often concurrent with HIV-associated dementia. Conventional investigations including neuroimaging, electroencephalography and cerebrospinal fluid analysis are necessary to exclude opportunistic infections or other disease processes (malignancy, stroke). While there is a theoretical risk of hepatic interactions between highly active antiretroviral therapy and first-line anticonvulsants (carbamazepine, phenytoin or valproic acid), these potential treatment side effects are rare if anticonvulsant blood levels are closely monitored. The use of gabapentin or levetiracetam as a second drug if the seizure disorder is not controlled by a single anti-convulsant is a comparatively safe option because they are cleared largely through the kidney. The overall prognosis for seizures in the context of HIV infection is good, especially if no focal pathogenic process is identified; patients often return to driving and employment if seizures are the only apparent neurological disorder.

Peripheral nervous system disorders of HIV-1 Infection

Distal sensory polyneuropathy

Peripheral neuropathy has become the major neurological complication of HIV infection in the developed world\(^68\). There are two major neuropathies associated with HIV\(^69\), which include the primary HIV-induced neuropathy, distal sensory polyneuropathy and antiretroviral toxic neuropathy, which is caused by antiretroviral drugs such as didanosine (ddI), zalcitabine (ddC), and stavudine (d4T)\(^65\), likely due to mitochondrial damage. However, recent studies suggest that protease inhibitors, especially the older protease inhibitors, including indinavir and saquinavir are associated with sensory neuropathy\(^70\). The prevalence of sensory neuropathy among HIV/AIDS patients in industrialized countries is 30-35%, depending on the diagnostic criteria\(^71\).

Clinical features

Both distal sensory and antiretroviral toxic neuropathies are usually defined by neuropathic pain, such as burning or aching sensations in the feet, paresthesiae, allodynia and hyperalgesia, beginning in the toes and soles of the feet that is often worse at night or after walking\(^68\). These symptoms are often sufficiently severe as to cause or exacerbate mental health issues. In addition, absent or reduced ankle deep tendon reflexes are evident with loss of pinprick, temperature or vibratory sensation (See clinical case). The relative paucity of signs and symptoms in the hands and arms suggests that both neuropathies are length-dependent phenomena. The symptoms and signs of distal sensory polyneuropathy and antiretroviral toxic neuropathy are identical and the two entities are distinguishable only by a history of recent onset neuropathy with initiation of a neurotoxic drug within several months (Table 4).

Diagnosis

Nerve conduction studies with electromyography are useful for excluding other conditions but may be normal in both distal sensory polyneuropathy and antiretroviral toxic neuropathy, as both syndromes usually involve small diameter fibers and are principally sensory neuropathies\(^72\). Nerve biopsies are also helpful in eliminating other diagnoses but the recent use of skin (punch) biopsies with analyses of epidermal innervation may be useful for diagnosis in the future\(^73\). Quantitative sensory testing is not routinely available but is helpful for evaluation of sensory thresholds, which are affected in both distal sensory polyneuropathy and antiretroviral toxic neuropathy. Serum lactate levels are usually not valuable in the diagnosis of antiretroviral toxic neuropathy despite evidence to suggest that mitochondrial dysfunction may contribute to the pathogenesis of antiretroviral toxic neuropathy\(^74\). It is helpful to document the severity of neuropathic pain at the time of diagnosis and during the course of treatment using established scales including the McGill Pain, Gracely or the Visual Analogue Scales for treatment assessment. It is also imperative to rule out other causes of painful sensory neuropathy such as diabetes, syphilis, nutritional deficiency, ethanol abuse and other neurotoxic drugs (metronidazole, ethambutol, vincristine, taxol, thalidomide and isoniazid)\(^75\).

Treatment

DSP usually shows improvement in untreated patients who begin on highly active antiretroviral therapy. It is important to avoid neurotoxic antiretroviral drugs that can exacerbate HIV-induced neuropathy. The treatment of antiretroviral toxic neuropathy necessitates elimination of the neurotoxic agent and implementing an alternative component into the highly active antiretroviral therapy regimen. In effect, the treatment modalities
Table 1: Definition of acquired immunodeficiency syndrome (AIDS)83

AIDS is defined as a CD4+ T lymphocyte count below 200 cells/μl of blood and/or the presence of an AIDS-defining illness including:

- HIV-associated dementia
- Opportunistic infections such as Pneumocystis jiroveci pneumonia, Kaposi’s sarcoma, Mycobacterium avium and tuberculosis, Cryptococcal meningitis, Toxoplasmic encephalitis, Progressive Multifocal Leukoencephalopathy, primary central nervous system lymphoma and cytomegalovirus encephalitis
- HIV wasting syndrome

Table 2: Other primary nervous system syndromes associated with HIV infection

- **Central Nervous System:**
  - *Aseptic Meningitis:* presents as part of the constellation of symptoms often associated with primary HIV infection/seroconversion84.
  - *Primary HIV-Induced Headache:* non-throbbing headache associated with photophobia with no other cause than HIV-1 infection85. Treatment with low dose tricyclic antidepressants can be effective.
  - *Neuromuscular disorders:*
    - Mononeuropathy Multiplex: asymmetric sensory and motor dysfunction affecting multiple nerves occurring over weeks is suggestive86.
    - *Diffuse Infiltrative Lymphocytosis Syndrome:* subacute sensorimotor neuropathy with neuopathic pain. Responds to highly active antiretroviral therapy in over 60% of patients although glucocorticoids may be useful in patients who do not respond to highly active antiretroviral therapy87.
    - *Guilliam-Barré Syndrome:* similar to sporadic Guillain-Barré Syndrome, treatment options include plasmapheresis or IVIG. Outcome is good for patients with CD4+ T cell counts above 200 cells/μl, although some residual weakness may linger88 but also increases susceptibility to other forms of peripheral neuropathy such as distal sensory polyneuropathy.
    - *Motor Neuron Disease Syndrome:* a amyotrophic lateral sclerosis-like syndrome rarely occurs in patients with HIV infection but responds to highly active antiretroviral therapy89.
    - *Entrapment/Mono-neuropathies Neuropathies:* predominantly carpal tunnel syndrome, meralgia paresthetica and radiculopathies88.
    - *Autonomic neuropathy:* present in 12% of HIV-1 seropositive patients, and is frequently observed in conjunction with distal sensory polyneuropathy with associated postural hypotension, gastroparesis and impotence90,91.
    - *Myopathies:* Proximal muscle weakness with or without myalgias and evidence of polymyositis (elevated creatine kinase or inflammation on biopsy). Other common myopathies are caused by zidovudine or HMG-CoA reductase inhibitors (statins)92.

Table 3: Clinical features of HIV-associated neurocognitive disorders (HIV-associated dementia and minor neurocognitive disorder)93

- Neurocognitive dysfunction: Memory impairment, poor concentration, psychomotor slowing.
- Emotional disturbance: Apathy and social withdrawal, which can be mistaken for depression. Also irritability, mental inflexibility, and decreased sex drive.
- Motor abnormalities: Weakness, ataxia, clumsy gait, slowing motor skills, tremor, diffuse increase in tone, hyperreflexia, spasticity, abnormal eye movements and parkinsonism. Frontal release signs and myoclonus in advanced stages of disease.
- Brain atrophy and abnormal subcortical white matter signal on magnetic resonance imaging and computerized tomography scanning.
- Pleocytosis, increased protein and high viral load in cerebrospinal fluid.
- Abnormal neuropsychological testing.

for both disorders require the use of a non-neurotoxic highly active antiretroviral therapy regimen. Importantly, zidovudine can cause a myopathy as a toxic side-effect, presenting with proximal muscle weakness and myalgias with occasionally elevated creatine kinase levels but it does not cause a peripheral neuropathy.

Clinical trials show that gabapentin is effective for symptomatic treatment of distal sensory polyneuropathy and antiretroviral toxic neuropathy96, likely through its actions on calcium channels. Similarly, pregabalin is a promising therapy for distal sensory polyneuropathy and antiretroviral toxic neuropathy although its mechanism is unknown but is probably similar to gabapentin. We have tended to avoid carbamazepine, lamotrigine and topiramate for control of neuropathic pain because of their potential ability to interact with highly active antiretroviral therapy in terms of hepatic metabolism and other side effects (leucopenia, sedation, or weight loss). While effective in the management of pain associated with non-HIV related peripheral neuropathies, clinical trials demonstrate that amitriptyline is minimally beneficial in the control of pain associated with distal sensory polyneuropathy97. A recent open label study indicates that a capsaicin-containing preparation, applied topically may be helpful in controlling neuropathy-associated pain in HIV infection98. Opioids are also highly effective in the control of neuropathic pain but raise the potential for drug dependence and may interfere with neurocognitive function in patients already at risk for HIV-associated Neurocognitive Disorder. Long acting opiates including fentanyl, methadone and slow-release morphine limit the problem of psychological dependence but can worsen prior neurocognitive impairment. An open-label study suggested that
human nerve growth factor may be useful for controlling distal sensory polyneuropathy-related pain symptom but other neurotrophins may be promising therapies for the future.

CONCLUSIONS AND FUTURE PERSPECTIVES

Given the rising prevalence of HIV/AIDS in both the industrialized and developing worlds, both established and newly recognized HIV-associated neuropsychiatric syndromes may become increasingly important. One topic of keen interest is the appearance and transmission of drug resistant HIV-1 strains whose associated neurological sequelae have not been well-described. Furthermore, the extent to which the central or peripheral nervous systems harbor potentially drug-resistant HIV is unknown. This circumstance might convert the nervous system into a virus reservoir, allowing the virus to seed the entire body unhindered because of the relative safety from the immune system provided by the blood-brain and -nerve barriers.

Table 4: Features of distal sensory polyneuropathy and antiretroviral toxic neuropathy

- Symptoms: symmetric burning or aching sensation, paresthesiae, dysesthesiae. Worsens as the day progresses, especially on the sole and dorsum of the feet, nocturnal awakening due to foot pain, rarely due to hand discomfort.
- Signs: stocking distribution loss of pain and temperature sensation, allodynia, hyperalgesia, diminished or absent distal deep tendon reflexes, atrophic skin changes in the feet and venous pooling.
- Abnormal nerve conduction (sensory) testing and sensory thresholds.
- Nerve and skin biopsies show loss of small diameter myelinated and unmyelinated fibres.

impact on the quality of life, longevity and cost to health care.

Question and Answer Section

Questions

1. What are the key clinical features of HIV-associated dementia?
2. Which diagnostic tests are required to establish the diagnosis of HIV-associated dementia?
3. What are the signs and symptoms that accompany HIV-related distal sensory polyneuropathy?
4. Which disorders are important to exclude in diagnosing HIV-related distal sensory polyneuropathy?
5. What is the first line treatment for HIV-related distal sensory polyneuropathy?

Answers

1. Cognitive impairment (forgetfulness, poor concentration and psychomotor slowing); Motor abnormalities (tremor, ataxia, spasticity); Behavioural changes (agitation, apathy).
2. Neuroimaging (MRI, CT); CSF analysis (exclude opportunistic infections); Neuropsychological testing (bedside and formal tests).
3. Pain (allodynia, hyperalgesia), numbness, paresthesiae; reduced ankle deep tendon reflexes, reduced temperature or vibration sensation.
4. Antiretroviral toxic neuropathy (ddC, D4T, ddI); diabetes; hypothyroidism; syphilis; nutritional deficiency (ethanol-related), other drugs associated with neuropathy (e.g. metronidazole, ethambutol, vincristin).
5. Gabapentin; long acting opiates.

ACKNOWLEDGEMENTS

The authors thank Drs. Anne Fanning and Joan Sametz for helpful comments and Stephanie Skinner and Leah DeBlock for assistance with manuscript preparation. CP holds a Canada Research Chair in Neurological Infection and Immunity and is an Alberta Heritage Foundation for Medical Research Senior Scholar.

REFERENCES


